Search
About
You are currently browsing the Drug Kennel weblog archives for the day Friday, October 31st, 2008.
Longer entries are truncated. Click the headline of an entry to read it in its entirety.
Latest
- Failed 505(b)(2)?: Vivus’ Qnexa
- Will We Have Generic User Fees? Public Meeting To Be Held.
- Lannett’s Morphine Sulfate Oral Solution: 505(b)(2) or 505j?
- Generic Lovenox – 505j or 505(b)(2)
- New User Fees for 2011
- Still submitting paper ANDA applications?
- What should a license cost?
- Avandia: Who Won?
- Advisory Committee Meeting: Rosiglitazone
- The skinny on a potential new treatment of obesity
Sertraline + CBT - a new 505(b)(2) Combo
Published October 31st, 2008 in 505(b)(2) Issues and News Commentary. 0 CommentsSeveral news sources report today (10/31/2008) that a new study shows that sertraline in combination with CBT eases anxiety in children. A number of 505(b)(2) development projects arise from observing these kinds of trials: an efficacy study shows that two (or more) concurrent treatments are safe and effective for a given set of indications. It [...]